In a major milestone, Professor Steve Pollard and his spin-out, Trogenix, have developed an innovative gene therapy could potentially eliminate gliobastoma and prevent them from coming back. In a preclinical trial using mice, more than 80% of mice saw a complete elimination of their brain tumour, with no toxicity and no tumour recurrence. In-human trials are scheduled to begin later this year. The cancer cell effectively becomes the source of its own destruction. We exploited what makes them cancer and turned their identity against them. We are all hoping this is finally something meaningful for glioblastoma patients and their families. Professor Steve Pollard Professor of Stem Cell and Cancer Biology; Associate Director, Cancer Research UK Scotland Centre Full story on Edinburgh Innovations Read the paper Tags 2026 Publication date 09 Apr, 2026
